A perspective on Synthetic Biology

Vincent Rouilly

MRes, December 2009

Next-Generation Sequencing SOLiD 3 Plus – a Systems Biology Tool

Michael Rhodes, Ph.D., Senior Manager Sequencing Portfolio, Applied Biosystems

Friday December 4th 2009

13:00 - 14:00h

Imperial College, South Kensington Campus Sir Alexander Fleming Building, 119 Seminar Room

Biotechnologies: a definition

 "Any technological application that uses biological systems, living organisms, or derivatives thereof, to make or modify products or processes for specific use."

United Nations Convention on Biological Diversity

The Biotechnology Landscape

- History
- Area of applications
- Technology toolbox
- Economy
- IP / Patent System
- Ethics and Social implications

Biotechnology Chronology

- Ancient time
- Age of Science
- Molecular biology era
- Genetic engineering era
- Genomics era
- Post-Genomics era

Biotech Companies / Market



Genentech \$ 9.2 billions





2% of US GDP (+20% year) - Rob Carlson

Biotechnologies: technologies

Enabling technologies

- Recombinant DNA
- DNA sequencing
- DNA synthesis
- High throughput technologies
- Computational analysis

Biotechnologies: applications

Applications and Successes

- Biofuels
- Biomaterials
- Biosensing
- Therapeutics
- Bioremediation
- Plant engineering


A Diverse Biotech Community

- Cellular Biologists
- Molecular Biologists
- Metabolic Engineers
- Protein Engineers
- Systems Biologists

Synthetic Biology

 How does Synthetic Biology fit into this existing Biotech landscape?

Synthetic Biology Textbook



Topic 1 Topic 2 Topic 3 Topic 4 Topic 5

Foundations for Synthetic Biology

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5

Standard for Physical DNA Composition

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5

Standards for Functional Composition

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5

Characterising Biological Parts

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5

Building Systems from BioBricks


Biotech Innovation Bottlenecks

- Innovation pipeline is slow
- Mass production / scale-up can be an issue
- Similarities with pre-Industrial period
- What made engineering disciplines so successful?

Synthetic biology success stories


- Seminal papers (Toggle Switch, Repressilator)
- Band-pass detector
- Edge detector
- PoPS amplifier
- Others ?

Current Trends in Synthetic Biology



- Speeding-up the development cycle
 - Building supporting technologies

Current Trends in Synthetic Biology



SynBio CAD Systems






Clotho

JBEIR







Current Trends in Synthetic Biology



Current Trends in Synthetic Biology



Current SynBio Challenges



No improvement if you can't reuse biological parts / experience Need for modularity and Decoupling

Current SynBio Challenges

Rules of composition (modularity)


- It is not because you have DNA BioBricks that you have a Modular Biology
- Biology appears to be a very context dependent language:
 - DNA RNA Protein Networks
 - See: RBS paper, promoter examples
- Inverter characterisation example
- Any other problematic composition ?

Composition rules: Promoters



Context dependent Promoter

Transcription initiation model




Context dependent RBS

nature biotechnology

Automated design of synthetic ribosome binding sites

to control protein expression

Howard M Salis1, Ethan A Mirsky2 & Christopher A Voigt1




Given a specific mRNA sequence—called the sub-sequence—surrounding a start codon, ΔG_{tot} is predicted according to an energy model (equation (2)), where the reference state is a fully unfolded sub-sequence with G = 0.

$$\Delta G_{tot} = \Delta G_{mRNA:rRNA} + \Delta G_{start} + \Delta G_{spacing} - \Delta G_{standby} - \Delta G_{mRNA} (2)$$

Context dependent CDS

Coding-Sequence Determinants of Gene Expression in *Escherichia coli*

Grzegorz Kudla,1* Andrew W. Murray,2 David Tollervey,3 Joshua B. Plotkin1†



Context dependent CDS (2)






Design Parameters to Control Synthetic Gene Expression in Escherichia coli

Mark Welch¹*, Sridhar Govindarajan¹, Jon E. Ness¹, Alan Villalobos¹, Austin Gurney², Jeremy Minshull¹, Claes Gustafsson¹

1 DNA2.0, Menlo Park, California, United States of America, 2 OncoMed Pharmaceuticals, Inc., Redwood City, California, United States of America



Current SynBio Challenges


- Measurements (Quality control)
 - Reliable and reproducible
 - Quantitative Measurements on the Central dogma:
 - DNA RNA Protein Network Phenotype Popu
 - Minimum Information Required initiative

Part Characterisation

Refinement and standardization biological parts and devices

Barry Canton^{1,4} Anna Labno^{2–4} & Drew Endy¹

Why does it break at some point?



DNA Parts Descriptors








Toward scalable parts families for predictable design of biological circuits

Julius B Lucks^{1,2}, Lei Qi³, Weston R Whitaker¹ and Adam P Arkin^{1,4}

Figure 1



Current SynBio Challenges

Standardisation

- DNA parts ?
- Measurements ?
- Reporting ?
- Request for Comments (RFC)
 - examples

Active projects in SynBio

- BioBrick standard + RFCs
- Automated DNA Assembly
- Promoter characterisation
- Chassis of choice (minimal, yeast, B. sub, E. coli)
- "POBOL": Description Language for BioBricks
- BioBrick Licensing Schema
- Ethical issues

Thank you

Any Further Questions?